Appropriate dose of regorafenib based on body weight of colorectal cancer patients: a retrospective cohort study.
BMC Cancer
; 23(1): 1268, 2023 Dec 21.
Article
em En
| MEDLINE
| ID: mdl-38129822
ABSTRACT
PURPOSE:
Previous randomized studies have shown a survival benefit of using regorafenib but a high rate of adverse events in unresectable colorectal cancer patients. To reduce these adverse events and improve the tolerability, we examined the appropriate dose of regorafenib based on body weight.METHODS:
We used a nationwide claims database in Japan and examined the efficacy and safety of regorafenib for patients with metastatic colorectal cancer between groups divided by body weight (60 kg) and median average dose (120 mg) between 2013 and 2018. We also assessed overall survival (OS) and adverse events between these groups.RESULTS:
We identified 2530 Japanese patients (heavy weight/high dose 513, light weight/low dose 921, heavy weight/low dose 452, and light weight/high dose 644). There was no significant difference in the adverse events and OS after inverse probability treatment weighting (IPTW) adjustment between heavy weight/high dose group and light weight/low dose group (hazard ratio, HR=0.97). Among the light-weight patients, higher average dose was associated with shorter OS (IPTW adjusted HR=1.21, 95% CI 1.05 - 1.39, Table 3) while among the heavy-weight patients, there was no significant difference in OS between high and low dose groups (IPTW adjusted HR=1.14, 95% CI 0.95 - 1.37).CONCLUSION:
The findings suggest that a low dose of regorafenib for light-weight patients may be as safe and effective as high doses for heavy-weight patients. Further studies should be conducted to identify an appropriate dose based on each patient's physique and condition.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Piridinas
/
Neoplasias Colorretais
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article